SCHEMBL4424892

SCHEMBL4424892

CC(C)(C)OC(=O)N1CCC(OCc2noc(-c3cccc(C(F)(F)F)c3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.51
CCR6 P51684 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
HDAC4 P56524 2/20 0.42
MGLL Q99685 1/20 0.42
DGAT2 Q96PD7 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
USP30 Q70CQ3 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA2B P29275 1/20 0.41
POLB P06746 1/20 0.41
TGFBR1 P36897 1/20 0.40
SCN9A Q15858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419641 0.89 GPR119 (0.54) GPR119CCR6MAPTPPARGPPARD
SCHEMBL14640891 0.88 GPR119 (0.53) GPR119CCR6USP30
SCHEMBL4421874 0.88 GPR119 (0.53) GPR119CCR6MAPTUSP30POLB
SCHEMBL4418527 0.87 GPR119 (0.58) GPR119
SCHEMBL4423385 0.87 GPR119 (0.54) GPR119CCR6HDAC4USP30
SCHEMBL4418911 0.85 GPR119 (0.53) GPR119CCR6USP30
SCHEMBL4416028 0.85 GPR119 (0.51) GPR119
SCHEMBL4412857 0.85 GPR119 (0.51) GPR119CCR6USP30
SCHEMBL4420059 0.83 GPR119 (0.51) GPR119
SCHEMBL13602326 0.83 GPR119 (0.51) GPR119HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885CCR6 1571/4885L3MBTL1 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.